Inversago Pharma Initiates a Phase 1 Clinical Trial on INV-202, a Next Generation Peripherally-acting CB1 Blocker
Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced that following the receipt of a No Objection Letter (NOL) from Health Canada on July 29, 2021, it has dosed the first volunteers with INV-202 in its first-in-human phase 1 clinical trial, which will evaluate the safety, tolerability and pharmacokinetics of this compound.
As a next generation peripheral CB1 inverse agonist / antagonist, INV-202 has the potential to treat various metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D), diabetic nephropathy and chronic kidney diseases, among others.
“Having demonstrated pharmacological characteristics that exceeded our expectations during IND-enabling preclinical studies, we’re excited to launch a second peripherally-acting CB1 blocker into the clinic with INV-202,” said Dr. Glenn Crater, MD, Chief Medical Officer of Inversago Pharma.
“With two unique, next generation CB1 blockers having entered the clinic in less than a year, we are rapidly bolstering our knowledge of this new class of drugs, which we believe may provide new treatment options for patients affected by a range of metabolic conditions,” said François Ravenelle, PhD, Chief Executive Officer of Inversago.
About INV-202
INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of several metabolic conditions. It is specifically designed to preferentially interact with peripheral CB1 receptors located in the gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs, thus aiming at a safe and effective therapeutic approach without the known liabilities of centrally-acting CB1 blockers. The peripheral CB1 blockade is a well-documented pathway, linked to many clinically meaningful metabolic benefits.
About Inversago Pharma
Headquartered in Montreal, Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as PWS, NASH, T1D and diabetic nephropathy. For more information, visit inversago.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005183/en/
Contact information
François Ravenelle, PhD
CEO & Founder
Inversago Pharma inc.
info@inversago.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mohammed bin Rashid Al Maktoum Global Water Award extends application deadline until end of May7.5.2024 20:01:00 CEST | Press release
The UAE Water Aid Foundation (Suqia UAE), under the umbrella of the Mohammed bin Rashid Al Maktoum Global Initiatives, has extended application deadline for the 4th cycle of the Mohammed bin Rashid Al Maktoum Global Water Award, with total prizes of USD 1 million. The award aims to find sustainable and innovative solutions to address water scarcity worldwide. Companies, research and development centres, research institutes, innovators, and youth can submit their applications until 31 May 2024. This encourages the development of innovative projects, technologies, and prototypes in water desalination and purification using renewable energy sources, including solar, wind, biomass, hydropower, osmotic power, and geothermal technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507709620/en/ Mohammed bin Rashid Al Maktoum Global Water Award extends application deadline until end of May (Graphic: AETOSWire) This award ref
Fields and the Sun: Agricultural PV, an Opportunity for the Energy and the Farming Industry7.5.2024 17:53:00 CEST | Press release
The EU’s objectives are ambitious: The total solar energy deployment is to reach around 750 gigawatts by 2030. In this context, dual land use concepts, especially agricultural PV, are gaining importance. At Intersolar Europe, the world’s leading exhibition for the solar industry, visitors will have the opportunity to see a varied range of technologies, products and solutions for agricultural PV, and to gain deeper insights into best practices and the latest developments. Intersolar Europe will take place from June 19–21, 2024 as part of The smarter E Europe, the continent’s largest alliance of exhibitions for the energy industry, in Munich. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507054567/en/ Latest tracking systems for agricultural PV applications will be presented at the "Intersolar Europe Special Exhibit Agrivoltaics". (© BayWa r.e.) Agriculture or renewable sources of energy – in the past, it was either, or. A
Verimatrix XTD Enterprise Suite Triumphs at 2024 Cybersecurity Excellence Awards7.5.2024 17:45:00 CEST | Press release
Regulatory News: Verimatrix, (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that its Verimatrix XTD Enterprise Suite won a prestigious 2024 Cybersecurity Excellence Award. This year’s accolade stands as the most recent honor in a multi-year series of award wins recognizing Verimatrix XTD as the trusted, enterprise-grade mobile application security solution of choice. The Verimatrix XTD Enterprise Suite has become the go-to cybersecurity solution for enterprises intent on shielding their iOS and Android applications from reverse engineering and other cyber attacks. Setting itself apart from the competition, Verimatrix offers versatile deployment options, including on-premises toolkits, zero-code cloud solutions, and a bespoke white glove service that ensures cybersecurity defenses are swiftly and cost-effectively implemented into DevSecOps workflows and continuous integration and continuous deployment (
Energy Vault Announces Successful Testing and Commissioning of First EVx 100 MWh Gravity Energy Storage System by China Tianying, Extension of Atlas Renewable Licensing Agreement to 15 Years7.5.2024 15:58:00 CEST | Press release
Energy Vault Holdings, Inc. (NYSE: NRGV) ("Energy Vault"), a leader in sustainable, grid-scale energy storage solutions, today announced the successful testing and commissioning of the Rudong EVx™ gravity energy storage system (GESS) by China Tianying Co., Ltd (CNTY). Testing included the successful charging and discharging of units of the 25 MW/100 MWh GESS invested in and built by CNTY in partnership with Energy Vault and Atlas Renewable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507725790/en/ The first set of charging and discharging units of the Rudong 100MWh gravity energy storage project was successfully tested. (Photo: Business Wire) In addition to the successful testing of the Rudong EVx, Energy Vault announced the extension of its EVx licensing agreement with Atlas Renewable from 7.5 to 15 years, reflecting the key role that gravity storage technology stands to play in China’s energy transition and achieving
Landmark Report Proves That High Nicotine Use Does Not Lead to High Rates of Health Issues7.5.2024 15:53:00 CEST | Press release
A new report released today in Stockholm by international health experts, "No Smoke, Less Harm" presents compelling evidence that despite similar levels of nicotine consumption, Sweden boasts significantly lower rates of tobacco-related diseases compared with other European nations. The report, which was unveiled during an event organised by Smoke Free Sweden, a global health advocacy group, details rates of nicotine usage in Sweden and a number of comparable countries, finding that nicotine use was not a factor in tobacco-related disease. Furthermore, the report provided further evidence that what does affect consumers’ health is the method of consumption. While using alternative products such as snus did not pose a significant risk, smoking is linked with a high incidence of death and disease. While nicotine consumption in Sweden mirrors the European average, the country reports a 41% lower incidence of lung cancer and fewer than half the tobacco-related deaths of its European peers.